Comprehensive Stock Comparison
Compare Immunome, Inc. (IMNM) vs Roivant Sciences Ltd. (ROIV) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ROIV | -11.2% revenue growth vs IMNM's -35.5% |
| Quality / Margins | IMNM | -23.0% net margin vs ROIV's -60.8% |
| Stability / Safety | ROIV | Beta 0.81 vs IMNM's 1.42, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ROIV | +169.5% vs IMNM's +132.6% |
| Efficiency (ROA) | ROIV | -15.5% ROA vs IMNM's -74.4%, ROIC -50.4% vs -7.0% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Immunome is a biopharmaceutical company that discovers and develops antibody therapeutics for cancer and infectious diseases. It generates revenue primarily through research collaborations and licensing agreements — with no commercial products yet — as it advances its pipeline of antibody candidates. The company's key advantage lies in its proprietary discovery platform that identifies human antibodies from patient immune responses, potentially yielding more effective and safer therapeutic candidates.
Roivant Sciences is a biopharmaceutical company that develops and commercializes innovative medicines across multiple therapeutic areas through its network of subsidiary "Vants." It generates revenue primarily from product sales of approved drugs — like its dermatology and immunology treatments — supplemented by licensing deals and research collaborations with larger pharmaceutical partners. Its key advantage is its decentralized "Vant" model, which allows for focused development of individual drug candidates while sharing centralized resources and expertise across the portfolio.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ROIV leads in 4 of 6 categories (Valuation Metrics, Profitability & Efficiency). IMNM leads in 1 (Financial Metrics).
Financial Metrics (TTM)
ROIV and IMNM operate at a comparable scale, with $13M and $10M in trailing revenue. IMNM is the more profitable business, keeping -23.0% of every revenue dollar as net income compared to ROIV's -60.8%. On growth, ROIV holds the edge at -77.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | IMNMImmunome, Inc. | ROIVRoivant Sciences … |
|---|---|---|
| RevenueTrailing 12 months | $10M | $13M |
| EBITDAEarnings before interest/tax | -$232M | -$1.2B |
| Net IncomeAfter-tax profit | -$223M | -$809M |
| Free Cash FlowCash after capex | -$192M | -$767M |
| Gross MarginGross profit ÷ Revenue | -4.2% | +91.2% |
| Operating MarginEBIT ÷ Revenue | -24.2% | -91.3% |
| Net MarginNet income ÷ Revenue | -23.0% | -60.8% |
| FCF MarginFCF ÷ Revenue | -19.8% | -57.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | -77.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +16.7% | -2.7% |
Valuation Metrics
| Metric | IMNMImmunome, Inc. | ROIVRoivant Sciences … |
|---|---|---|
| Market CapShares × price | $2.0B | $1.1B |
| Enterprise ValueMkt cap + debt − cash | $1.9B | -$1.5B |
| Trailing P/EPrice ÷ TTM EPS | -4.37x | -120.58x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 221.74x | 38.70x |
| Price / BookPrice ÷ Book value/share | 7.08x | 4.05x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
ROIV delivers a -16.3% return on equity — every $100 of shareholder capital generates $-16 in annual profit, vs $-84 for IMNM. ROIV carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to IMNM's 0.03x. On the Piotroski fundamental quality scale (0–9), ROIV scores 5/9 vs IMNM's 1/9, reflecting solid financial health.
| Metric | IMNMImmunome, Inc. | ROIVRoivant Sciences … |
|---|---|---|
| ROE (TTM)Return on equity | -84.4% | -16.3% |
| ROA (TTM)Return on assets | -74.4% | -15.5% |
| ROICReturn on invested capital | -7.0% | -50.4% |
| ROCEReturn on capital employed | -195.6% | -16.4% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 5 |
| Debt / EquityFinancial leverage | 0.03x | 0.02x |
| Net DebtTotal debt minus cash | -$139M | -$2.6B |
| Cash & Equiv.Liquid assets | $143M | $2.7B |
| Total DebtShort + long-term debt | $5M | $100M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (with DRIP)
A $10,000 investment in ROIV five years ago would be worth $28,456 today (with dividends reinvested), compared to $5,472 for IMNM. Over the past 12 months, ROIV leads with a +169.5% total return vs IMNM's +132.6%. The 3-year compound annual growth rate (CAGR) favors IMNM at 68.5% vs ROIV's 52.9% — a key indicator of consistent wealth creation.
| Metric | IMNMImmunome, Inc. | ROIVRoivant Sciences … |
|---|---|---|
| YTD ReturnYear-to-date | +5.0% | +32.0% |
| 1-Year ReturnPast 12 months | +132.6% | +169.5% |
| 3-Year ReturnCumulative with dividends | +378.3% | +257.7% |
| 5-Year ReturnCumulative with dividends | -45.3% | +184.6% |
| 10-Year ReturnCumulative with dividends | +62.5% | +178.3% |
| CAGR (3Y)Annualised 3-year return | +68.5% | +52.9% |
Risk & Volatility
ROIV is the less volatile stock with a 0.81 beta — it tends to amplify market swings less than IMNM's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ROIV currently trades 99.1% from its 52-week high vs IMNM's 79.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IMNMImmunome, Inc. | ROIVRoivant Sciences … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.42x | 0.81x |
| 52-Week HighHighest price in past year | $27.65 | $29.20 |
| 52-Week LowLowest price in past year | $5.15 | $8.73 |
| % of 52W HighCurrent price vs 52-week peak | +79.1% | +99.1% |
| RSI (14)Momentum oscillator 0–100 | 42.9 | 72.1 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 5.6M |
Analyst Outlook
Wall Street rates IMNM as "Buy" and ROIV as "Buy". Consensus price targets imply 61.4% upside for IMNM (target: $35) vs 8.0% for ROIV (target: $31).
| Metric | IMNMImmunome, Inc. | ROIVRoivant Sciences … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $35.29 | $31.25 |
| # AnalystsCovering analysts | 9 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +100.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jan 21 | Feb 26 | Change |
|---|---|---|---|
| Immunome, Inc. (IMNM) | 100 | 268.1 | +168.1% |
| Roivant Sciences Lt… (ROIV) | 97.79 | 210.96 | +115.7% |
Roivant Sciences Lt… (ROIV) returned +185% over 5 years vs Immunome, Inc. (IMNM)'s -45%. A $10,000 investment in ROIV 5 years ago would be worth $28,456 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2018 | 2024 | Change |
|---|---|---|---|
| Immunome, Inc. (IMNM) | $0.00 | $9M | — |
| Roivant Sciences Lt… (ROIV) | $68M | $29M | -57.1% |
Immunome, Inc.'s revenue grew from $0M (2018) to $9M (2024) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2019 | 2024 | Change |
|---|---|---|---|
| Immunome, Inc. (IMNM) | -7.6% | -32.4% | -325.3% |
| Roivant Sciences Lt… (ROIV) | 17.7% | -5.9% | -133.4% |
Roivant Sciences Ltd.'s net margin went from 18% (2019) to -6% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2018 | 2024 | Change |
|---|---|---|---|
| Immunome, Inc. (IMNM) | -7.18 | -5 | +30.4% |
| Roivant Sciences Lt… (ROIV) | 1.75 | -0.24 | -113.7% |
Immunome, Inc.'s EPS grew from $-7.18 (2018) to $-5.00 (2024).
Chart 5Free Cash Flow — 5 Years
Immunome, Inc. generated $-164M FCF in 2024 (-798% vs 2021). Roivant Sciences Ltd. generated $-844M FCF in 2024 (-21% vs 2021).
IMNM vs ROIV: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is IMNM or ROIV a better buy right now?
Analysts rate Immunome, Inc. (IMNM) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IMNM or ROIV?
Over the past 5 years, Roivant Sciences Ltd. (ROIV) delivered a total return of +184.6%, compared to -45.3% for Immunome, Inc. (IMNM). A $10,000 investment in ROIV five years ago would be worth approximately $28K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ROIV returned +178.3% versus IMNM's +62.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IMNM or ROIV?
By beta (market sensitivity over 5 years), Roivant Sciences Ltd. (ROIV) is the lower-risk stock at 0.81β versus Immunome, Inc.'s 1.42β — meaning IMNM is approximately 74% more volatile than ROIV relative to the S&P 500. On balance sheet safety, Roivant Sciences Ltd. (ROIV) carries a lower debt/equity ratio of 2% versus 3% for Immunome, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — IMNM or ROIV?
Roivant Sciences Ltd. (ROIV) is the more profitable company, earning -592.0% net margin versus -32.4% for Immunome, Inc. — meaning it keeps -592.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMNM leads at -33.8% versus -34.5% for ROIV. At the gross margin level — before operating expenses — IMNM leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — IMNM or ROIV?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is IMNM or ROIV better for a retirement portfolio?
For long-horizon retirement investors, Roivant Sciences Ltd. (ROIV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.81), +178.3% 10Y return). Both have compounded well over 10 years (ROIV: +178.3%, IMNM: +62.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between IMNM and ROIV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.